- Home
- ELVN vs BBDC Comparison
ELVN vs BBDC Comparison
Compare ELVN & BBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- BBDC
- Stock Information
- Founded
- ELVN 2016
- BBDC 2006
- Country
- ELVN United States
- BBDC United States
- Employees
- ELVN N/A
- BBDC N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- BBDC Diversified Financial Services
- Sector
- ELVN Health Care
- BBDC Finance
- Exchange
- ELVN Nasdaq
- BBDC Nasdaq
- Market Cap
- ELVN 927.8M
- BBDC 961.0M
- IPO Year
- ELVN 2020
- BBDC 2007
- Fundamental
- Price
- ELVN $20.73
- BBDC $9.28
- Analyst Decision
- ELVN Strong Buy
- BBDC Buy
- Analyst Count
- ELVN 5
- BBDC 3
- Target Price
- ELVN $41.20
- BBDC $9.67
- AVG Volume (30 Days)
- ELVN 734.1K
- BBDC 416.4K
- Earning Date
- ELVN 08-12-2025
- BBDC 08-06-2025
- Dividend Yield
- ELVN N/A
- BBDC 11.21%
- EPS Growth
- ELVN N/A
- BBDC N/A
- EPS
- ELVN N/A
- BBDC 0.94
- Revenue
- ELVN N/A
- BBDC $280,800,000.00
- Revenue This Year
- ELVN N/A
- BBDC N/A
- Revenue Next Year
- ELVN N/A
- BBDC N/A
- P/E Ratio
- ELVN N/A
- BBDC $9.91
- Revenue Growth
- ELVN N/A
- BBDC N/A
- 52 Week Low
- ELVN $13.30
- BBDC $7.66
- 52 Week High
- ELVN $30.03
- BBDC $10.85
- Technical
- Relative Strength Index (RSI)
- ELVN 52.36
- BBDC 59.33
- Support Level
- ELVN $19.22
- BBDC $8.98
- Resistance Level
- ELVN $21.90
- BBDC $9.18
- Average True Range (ATR)
- ELVN 1.46
- BBDC 0.11
- MACD
- ELVN -0.19
- BBDC 0.02
- Stochastic Oscillator
- ELVN 40.50
- BBDC 97.44
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About BBDC Barings BDC Inc.
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.